

SUPPLEMENTARY DATA

Supplementary Table 1. Comparison of outcomes using one-year, four-year, and seven-year lag between BP and outcome ascertainment in fully adjusted models.

Hazard ratio* (95% CI)	One-year lag between BP ascertainment and outcomes	Four-year lag between BP ascertainment and outcomes	Seven-year lag between BP ascertainment and outcomes
Macroalbuminuria			
Systolic BP			
Every 10 mm Hg increase in SBP	1.44 (1.28-1.62)	1.06 (0.92-1.22)	1.11 (0.95-1.30)
130-<140 mm Hg	Reference	1.0 (Ref)	1.0 (Ref)
120-<130 mm Hg	0.84 (0.53-1.36)	0.70 (0.44-1.12)	1.19 (0.61-2.32)
<120 mm Hg	0.59 (0.37-0.95)	0.63 (0.40-0.99)	1.12 (0.59-2.12)
Diastolic BP			
Every 10 mm Hg increase in SBP	1.32 (1.10-1.59)	1.16 (0.96-1.40)	1.15 (0.93-1.44)
80-<90 mm Hg	Reference	Reference	Reference
70-<80 mm Hg	0.71 (0.48-1.04)	0.96 (0.66-1.39)	0.76 (0.50-1.17)
<70 mm Hg	0.73 (0.44-1.18)	0.65 (0.39-1.10)	0.79 (0.48-1.32)
CKD Stage III			
Systolic BP			
Every 10 mm Hg increase in SBP	1.34 (1.16-1.54)	1.29 (1.12-1.50)	1.26 (1.07-1.47)
130-<140 mm Hg	1.0 (Ref)	1.0 (Ref)	1.0 (Ref)
120-<130 mm Hg	1.46 (0.75-2.83)	0.82 (0.42-1.61)	0.86 (0.45-1.62)
<120 mm Hg	0.32 (0.14-0.75)	0.62 (0.32-1.21)	0.50 (0.27-0.96)
Diastolic BP			
Every 10 mm Hg increase in DBP	1.41 (1.09-1.82)	1.56 (1.21-2.01)	1.36 (1.05-1.76)
80-<90 mm Hg	1.0 (Ref)	1.0 (Ref)	1.0 (Ref)
70-<80 mm Hg	1.11 (0.61-2.01)	0.63 (0.38-1.07)	0.54 (0.32-0.92)
<70 mm Hg	0.47 (0.21-1.05)	0.42 (0.20-0.86)	0.49 (0.26-0.94)

* Adjusted for age, sex, race, education, family history of hypertension, trial arm, and time-dependent lagged covariates including hemoglobin A1C, body mass index, smoking status, use of any anti-hypertensive medication, use of RAAS blockade (ACE inhibitor or ARB), albuminuria, and eGFR, and stratified by primary or secondary prevention cohort.